Carlsmed’s aprevo implant for lumbar spine surgery had reduced complication-related reoperations compared to conventional stock devices, according to two-year data.
The study, published in Global Spine Journal, evaluated the patient-specific aprevo device in complex adult spinal deformity patients, according to a Jan. 7 news release.
Five things to know:
1. The study included 115 adult spinal deformity patients who had surgery with an aprevo device and 997 patients who had stock devices. All had at least two years of follow up data.
2. The cohort using aprevo implants had a complication revision rate of 4.3%, The group with stock devices had a 16.6% reoperation rate.
3. The study concluded, “These findings suggest that achieving planned alignment targets with personalized interbody devices is associated with reduced revision surgery for mechanical complications, a result which may have positive implications for improved patient outcomes and reduced cost.”
4. Carlsmed’s aprevo devices leverage 3D printing and AI to crate patient-specific implants to enable predictable alignment.
5. “Previously published clinical data has demonstrated that 3D surgical planning combined with patient-specific interbody implants help surgeons achieve the personalized alignment goals and endplate fit that are unique to each patient,” Carlsmed CEO Mike Cordonnier, said in a news release. “These new findings further validate the clinical value of personalization in spine surgery, improving outcomes, improving quality of life, reducing reoperations and lowering the overall economic burden associated with revision procedures.”
